{
  "question_stem": {
    "en": "A 60-year-old man comes to the hospital with chest pain. He has had intermittent, squeezing substernal pain over the last 3 days that is now sustained. The patient has no associated palpitations, lightheadedness, or shortness of breath. Medical history is notable for moderate chronic obstructive pulmonary disease with a recent admission for an exacerbation. Blood pressure is 145/90 mm Hg and pulse is 93/min. Oxygen saturation by pulse oximetry is 98% on room air. Physical examination shows no heart murmurs, and lungs are clear to auscultation. ECG shows sinus rhythm with 2-mm anterior ST segment elevation. Cardiac troponin I levels are elevated.",
    "zh": "一名60岁男性因胸痛就诊。过去3天来，他一直有间歇性、压榨性胸骨后疼痛，现在疼痛持续。患者没有相关的心悸、头晕或呼吸短促。病史显示有中度慢性阻塞性肺病，近期因病情加重而入院。血压为145/90 mmHg，脉搏为93次/分。通过脉搏血氧仪测得的氧饱和度在常氧下为98%。体格检查显示无心脏杂音，肺部听诊清晰。心电图显示窦性心律，前壁ST段抬高2 mm。心肌肌钙蛋白I水平升高。"
  },
  "question": {
    "en": "Which of the following is the most appropriate treatment for this patient?",
    "zh": "以下哪项是该患者最合适的治疗方法？"
  },
  "options": {
    "A": {
      "en": "Ibutilide",
      "zh": "伊布利特"
    },
    "B": {
      "en": "Metoprolol",
      "zh": "美托洛尔"
    },
    "C": {
      "en": "Nadolol",
      "zh": "纳多洛尔"
    },
    "D": {
      "en": "Propranolol",
      "zh": "普萘洛尔"
    },
    "E": {
      "en": "Sotalol",
      "zh": "索他洛尔"
    }
  },
  "correct_answer": "B",
  "explanation": {
    "en": "This patient’s clinical presentation—chest discomfort, ST elevation on ECG, elevated troponin I level—is consistent with ACUTE MYOCARDIAL INFARCTION (AMI). Beta blockers are used in AMI to reduce myocardial oxygen demand by lowering heart rate, cardiac contractility, and afterload. They have been shown to reduce short-term morbidity (eg, recurrent symptoms or reinfarction), minimize infarct size, and improve long-term survival.\n\nContraindications to beta blockers include bradycardia or heart block, hypotension, and overt heart failure (eg, pulmonary edema). Also, non-cardioselective beta blockers (eg, propranolol, nadolol) can trigger bronchospasm in patients with underlying obstructive lung disease (asthma, CHRONIC OBSTRUCTIVE PULMONARY DISEASE [COPD]) due to beta-2 receptor blockade and should be avoided (Choices C and D).\n\nCardioselective beta blockers with predominant action on beta-1 receptors (eg, metoprolol, atenolol, bisoprolol, nebivolol) are safe in patients with stable obstructive lung disease and are the beta blocker of choice in these patients. Combined beta and alpha receptor blockers (eg, carvedilol, labetalol) are also well tolerated and have been used safely in patients with COPD.\n\n(Choice A) Ibutilide is a class III antiarrhythmic drug (potassium channel blocker) used for acute termination of atrial flutter or atrial fibrillation. Like other class III antiarrhythmics, ibutilide causes prolonged QT interval that can precipitate a deadly arrhythmia (torsade de pointes).\n\n(Choice E) Sotalol is a class III antiarrhythmic drug with beta blocker properties and is primarily used for the treatment of atrial and ventricular arrhythmias. It would not be indicated in a patient with a recent myocardial infarction who is in sinus rhythm.",
    "zh": "该患者的临床表现——胸部不适、心电图ST段抬高、肌钙蛋白I水平升高——与急性心肌梗死（AMI）一致。β受体阻滞剂用于AMI，通过降低心率、心脏收缩力和后负荷来降低心肌耗氧量。它们已被证明可以降低短期发病率（例如，复发症状或再梗死）、最大限度地减小梗死面积并提高长期生存率。\n\nβ受体阻滞剂的禁忌症包括心动过缓或心脏传导阻滞、低血压和显性心力衰竭（例如，肺水肿）。此外，非选择性β受体阻滞剂（例如，普萘洛尔、纳多洛尔）可在患有潜在阻塞性肺病（哮喘、慢性阻塞性肺病[COPD]）的患者中触发支气管痉挛，这归因于β-2受体阻滞，应避免使用（选项C和D）。\n\n对β-1受体有主要作用的、具有心脏选择性的β受体阻滞剂（例如，美托洛尔、阿替洛尔、比索洛尔、奈必洛尔）对患有稳定阻塞性肺病的患者是安全的，并且是这些患者的首选β受体阻滞剂。联合β受体和α受体阻滞剂（例如，卡维地洛、拉贝洛尔）也具有良好的耐受性，并已在COPD患者中安全使用。\n\n（选项A）伊布利特是一种III类抗心律失常药物（钾通道阻滞剂），用于急性终止房扑或房颤。与其他III类抗心律失常药一样，伊布利特会导致QT间期延长，从而可能诱发致命的心律失常（尖端扭转型室速）。\n\n（选项E）索他洛尔是一种具有β受体阻滞剂特性的III类抗心律失常药物，主要用于治疗房性心律失常和室性心律失常。它不适用于近期发生心肌梗死且窦性心律的患者。"
  },
  "summary": {
    "en": "This question tests knowledge of appropriate management of acute myocardial infarction in a patient with COPD, focusing on the selection of beta-blockers. The key is to recognize the contraindications of non-selective beta-blockers in patients with COPD and choose a cardioselective beta-blocker.\n\nTo solve this question, identify the patient's acute myocardial infarction based on the ECG and troponin levels. Then, consider the patient's COPD and the potential for bronchospasm with non-selective beta-blockers, leading to the selection of a cardioselective beta-blocker like metoprolol.",
    "zh": "此问题考察对COPD患者急性心肌梗死的适当处理知识，重点在于选择β受体阻滞剂。关键在于认识到非选择性β受体阻滞剂在COPD患者中的禁忌症，并选择一种心脏选择性β受体阻滞剂。\n\n要解决此问题，请根据心电图和肌钙蛋白水平确定患者的急性心肌梗死。然后，考虑患者的COPD以及非选择性β受体阻滞剂引起支气管痉挛的可能性，从而选择一种心脏选择性β受体阻滞剂，如美托洛尔。"
  },
  "tags": "Acute myocardial infarction; Beta-blockers; Chronic obstructive pulmonary disease; Cardiology; Emergency medicine; ST elevation; Troponin; Metoprolol; Bronchospasm",
  "category": "CVS",
  "question_id": "1196",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\1196",
  "extracted_at": "2025-11-05T11:52:34.311081",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:44:41.462573",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}